Breast cancer patients who respond to tamoxifen and other estrogen-antagonizing drugs can succumb to disease when cancer growth becomes independent of the hormone. One protein, Efp, that might have a role in estrogen independence has now been linked to proteolytic events in the cell cycle.
- Grzegorz Nalepa
- J. Wade Harper
